Viruses Causing Common Respiratory Infection in Man. IV. Reoviruses and Adenoviruses

Jackson, George Gee; Muldoon, Robert L.

doi:10.1093/infdis/128.6.811

Cited by 56 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This, combined with the fact that reovirus possesses a highly stable unenveloped icosahedral capsid, explains why as many as 50% of adults aged 20-30 years have been exposed to reovirus over the course of their lives and thus carry antibodies against the virus (9). Seropositivity has been documented to be as high as 70-100% of subjects in some studies (10,11), despite the fact that most reovirus infections go unnoticed.…”

Section: Introductionmentioning

confidence: 99%

Reovirus as a novel oncolytic agent

Norman

Lee²

2000

J. Clin. Invest.

110

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Reovirus as a novel oncolytic agent

Norman

Lee²

2000

J. Clin. Invest.

110

View full text Add to dashboard Cite

“…Reovirus has been isolated from the respiratory and gastrointestinal tracts and is referred to as an "orphan" virus because infection is asymptomatic (7). In the United States, as many as 63% of adults 20 to 30 years of age carry antibodies against reovirus; in children 1 to 5 years of age, 10% have antibodies against reovirus (8). Taxonomically, reovirus is a member of the Reoviridae viral family.…”

Section: Reovirusmentioning

confidence: 99%

“…More commonly, reovirus infects cells in the respiratory and gastrointestinal tracts (22). As many as 50% of adults ages 20 to 30 years carry antibodies against the virus and in some studies up to 100% seropositivity in adult populations has been reported (8,23). The prevalence of seropositivity among potential patients may limit the potency of therapeutic reovirus administration.…”

Section: Reovirusmentioning

confidence: 99%

Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus

Zhao

Chester

Rajasekaran

et al. 2016

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The dominant cancer treatment modalities such as chemotherapy, radiotherapy, and even targeted kinase inhibitors and mAbs are limited by low efficacy, toxicity, and treatmentresistant tumor subclones. Oncolytic viral therapy offers a novel therapeutic strategy that has the potential to dramatically improve clinical outcomes. Reovirus, a double-stranded benign human RNA virus, is a leading candidate for therapeutic development and currently in phase III trials. Reovirus selectively targets transformed cells with activated Ras signaling pathways; Ras genes are some of the most frequently mutated oncogenes in human cancer and it is estimated that at least 30% of all human tumors exhibit aberrant Ras signaling. By targeting Rasactivated cells, reovirus can directly lyse cancer cells, disrupt tumor immunosuppressive mechanisms, reestablish multicellular immune surveillance, and generate robust antitumor responses. Reovirus therapy is currently being tested in combination with radiotherapy, chemotherapy, immunotherapy, and surgery. In this review, we discuss the current successes of these combinatorial therapeutic strategies and emphasize the importance of prioritizing combination oncolytic viral therapy as reovirus-based treatments progress in clinical development.

show abstract

“…135 Three viral serotypes have been isolated and all are commonly found in the environment as this virus possesses a highly stable unenveloped icosahedral capsid, thus it is estimated that nearly half of the population has been exposed and carries antibodies to the virus. [136][137][138] Importantly, reovirus type 3 Dearing strain exhibits replication in cells with an activated Ras signaling pathway, a significant finding because of the link between oncogenesis and mutations in the ras gene and pathway, and it has been demonstrated that this is due to inhibition of double-stranded RNA-activated protein kinase resulting in cell lysis. 139,140 Although normal mouse fibroblast cells (NIH3T3) do not normally support reovirus replication, NIH3T3 cells transformed with activated ras, epidermal growth factor receptor or V-erb B oncogene (for example, activated ras pathway elements) are lysed by uninhibited reovirus replication.…”

Section: Reovirusmentioning

confidence: 99%

Clinical development directions in oncolytic viral therapy

Eager

Nemunaitis

2011

Cancer Gene Ther

View full text Add to dashboard Cite

Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicativecompetent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested in a variety of tumors. This review will provide a brief description of these novel anticancer biologics and will summarize the results of clinical investigation. To date oncolytic virotherapy has shown to be safe, and has generated clinical responses in tumors that are resistant to chemotherapy or radiotherapy. The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms.

show abstract

Viruses Causing Common Respiratory Infection in Man. IV. Reoviruses and Adenoviruses

Cited by 56 publications

References 0 publications

Reovirus as a novel oncolytic agent

Reovirus as a novel oncolytic agent

Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus

Clinical development directions in oncolytic viral therapy

Contact Info

Product

Resources

About